Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the absence of definitive medical treatment for severe fulminant hepatic failure, liver transplantation may be appropriate in selected patients. However, uniform and easily applicable criteria for diagnosis of severity and analysis of results are needed to prevent unnecessary transplantation and to ensure that patients who may benefit are appropriately treated. Previous regimens for treatment of fulminant hepatic failure were often advocated, on the basis of data from historical controls, for several years until controlled trials failed to show any benefit. To obtain reliable information more rapidly than achieved before, a controlled trial between specialist liver transplant units is needed to establish the role of emergency hepatic transplantation in patients with fulminant hepatic failure.


Journal article



Publication Date





32 - 35


Biomedical and Behavioral Research, Health Care and Public Health, Professional Patient Relationship, Acute Disease, Bias, Control Groups, Ethics, Medical, Hemoperfusion, Hepatic Encephalopathy, Humans, Liver Transplantation, Patient Selection, Prognosis, Randomized Controlled Trials as Topic, Renal Dialysis, Research Subjects, Risk Assessment, Severity of Illness Index, Therapeutic Human Experimentation